

Synclar-250

Clarithromycin Tablets USP 250 mg

Cipla

THE ADVANCED MACROLIDE

Wide coverage of gram-positive, gram-negative and atypical pathogens^{1,2,3}

Organisms	Clarithromycin (Synclar)	Erythromycin	Cefaclor	Amoxicillin-clavulanic acid
Gram-positive				
<i>S. aureus, methicillin susceptible</i>	+	+	+	+
<i>S. pyogenes</i>	+	+	+	+
<i>S. pneumoniae</i>	+	+	+	+
Gram-negative				
<i>H. influenzae</i>	+	-	+	+
<i>M. catarrhalis</i>	+	+	+	+
<i>N. gonorrhoeae</i>	+	+	+	+
<i>H. pylori</i>	+	+	-	-
Atypical				
<i>M. pneumoniae</i>	+	+	-	-
<i>C. pneumoniae</i>	+	+	-	-
<i>C. trachomatis</i>	+	+	-	-
<i>L. pneumophila</i>	+	+	-	-


- Good intracellular penetration⁴
- Enhanced post-antibiotic effect⁵
- Safe and well tolerated⁶

Antibacterial activity that continues even after metabolism

Enhanced activity against *Haemophilus influenzae*

"A novel aspect of clarithromycin (*Synclar*) is that it has a metabolite which is twice as active as the parent compound against *H. influenzae*. Moreover a synergistic or additive interaction between the two compounds has been demonstrated in vitro against *H. influenzae*.⁷

Effect of combining clarithromycin (Synclar) and its 14-hydroxy metabolite on the viability of H.influenzae⁸



Synclar-250

Clarithromycin Tablets USP 250 mg

Cipla

THE ADVANCED MACROLIDE

High tissue concentrations

"In the respiratory tract of patients, clarithromycin (**Synclar**) rapidly achieves concentrations that exceed those in plasma."⁹

Tissue/Fluid	Tissue/fluid conc. mg/kg or mg/L	Plasma conc. mg/L	Tissue : plasma ratio
Lung Tissue	54.32	1.89	28.7
Epithelial lining fluid	20.46	3.96	5.17
Alveolar macrophages	372.7	3.96	94.1
Bronchial secretions	1.1	0.36	3.1
Tonsils	2.12	0.0064	331.0
Nasal mucosa	2.2	0.08	27.5
Middle ear fluid	7.38	0.68	8.82

References

1. Curr. Ther. Res. 1995; 56(5):469
2. Drugs 1992; 44(1):124, 126
3. Drugs Facts and Comparisons 1996; 50th ed.:1960, 2008
4. Drugs 1992;44(1):134
5. Drugs 1992;44(1):133
6. Drugs Safety 1993;8(5):357-63
7. J. Antimicrob. Chemo 1991;27(Suppl.A):28
8. Antimicrob. Ag. Chemo. 1990;34(7):1410
9. Drugs 1997; 53(6):982-83

Cipla – Your Healthcare Partner Since 1935

Produced by **CIPLA**, a leading provider of generic pharmaceuticals.

Key Facts about CIPLA:

- 25 manufacturing facilities approved by leading regulatory authorities including the FDA (USA), MHRA (U.K.) and TGA (Australia).
- Over 1000 Formulations and 150 Active Pharmaceutical Ingredients.
- Prequalified and Approved by the World Health Organisation (WHO) for supply to UN Agencies.
- The World's largest range of antiasthmatic aerosols and inhalation devices.
- The World's largest manufacturer of antiretroviral drugs and supplier to the Clinton Foundation AIDS/HIV Initiative.

Distributed by
Controlled Medications Ltd
Unit 204, 2/F New Bright Building
11 Sheung Yuet Road, Kowloon Bay
Kowloon, Hong Kong
Tel: (852) 2896 0889
Fax: (852) 2898 9842
www.swedishtrading.com/conmed

conmed
Controlled Medications Ltd.
康德行有限公司